EE05497B1 - Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha - Google Patents

Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha

Info

Publication number
EE05497B1
EE05497B1 EEP200100472A EEP200100472A EE05497B1 EE 05497 B1 EE05497 B1 EE 05497B1 EE P200100472 A EEP200100472 A EE P200100472A EE P200100472 A EEP200100472 A EE P200100472A EE 05497 B1 EE05497 B1 EE 05497B1
Authority
EE
Estonia
Prior art keywords
polypeptide
cram
polynucleotide
antibody
soluble
Prior art date
Application number
EEP200100472A
Other languages
English (en)
Estonian (et)
Inventor
Albert Imhof Beat
Aurrand-Lions Michel
Original Assignee
Rmf Dictagene S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rmf Dictagene S.A. filed Critical Rmf Dictagene S.A.
Publication of EE200100472A publication Critical patent/EE200100472A/xx
Publication of EE05497B1 publication Critical patent/EE05497B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200100472A 1999-03-11 2000-03-13 Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha EE05497B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99200746 1999-03-11
PCT/EP2000/002219 WO2000053749A2 (en) 1999-03-11 2000-03-13 Vascular adhesion molecules and modulation of their function

Publications (2)

Publication Number Publication Date
EE200100472A EE200100472A (et) 2002-12-16
EE05497B1 true EE05497B1 (et) 2011-12-15

Family

ID=8239973

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100472A EE05497B1 (et) 1999-03-11 2000-03-13 Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha

Country Status (23)

Country Link
US (3) US7393651B2 (xx)
EP (2) EP1163337B1 (xx)
JP (2) JP4836329B2 (xx)
CN (2) CN1637019A (xx)
AT (1) ATE500328T1 (xx)
AU (1) AU782139B2 (xx)
BR (1) BR0008915A (xx)
CA (1) CA2362896C (xx)
CZ (1) CZ303128B6 (xx)
DE (1) DE60045681D1 (xx)
EE (1) EE05497B1 (xx)
ES (1) ES2361905T3 (xx)
HK (1) HK1044169A1 (xx)
HU (1) HU229376B1 (xx)
IL (1) IL145310A0 (xx)
IS (1) IS2819B (xx)
MX (1) MXPA01009110A (xx)
NO (1) NO333085B1 (xx)
NZ (1) NZ514091A (xx)
PL (1) PL207994B1 (xx)
RU (1) RU2244748C2 (xx)
WO (1) WO2000053749A2 (xx)
ZA (1) ZA200107283B (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
EE05497B1 (et) * 1999-03-11 2011-12-15 Rmf Dictagene S.A. Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
GB0100750D0 (en) * 2001-01-11 2001-02-21 Inpharmatica Ltd Novel proteins
WO2003006673A2 (en) * 2001-07-11 2003-01-23 Texas Biotechnology Corporation A nucleic acid encoding a human junctional adhesion protein (jam3)
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP1533617A1 (en) * 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
CN107929731A (zh) 2005-11-04 2018-04-20 健泰科生物技术公司 利用补体途径抑制剂治疗眼部疾病
RU2464030C2 (ru) * 2006-05-26 2012-10-20 Регадо Байосайенсиз, Инк. Введение противосвертывающей системы reg1
US8007797B2 (en) 2006-09-28 2011-08-30 Merck Serono S.A. Junctional adhesion molecule-C (JAM-C) binding compounds and methods of their use
ES2700609T3 (es) 2006-11-02 2019-02-18 Genentech Inc Anticuerpos anti-factor D humanizados y sus usos
FR2909092B1 (fr) * 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
PL2190991T3 (pl) * 2007-08-06 2020-05-18 Noxxon Pharma Ag Kwasy nukleinowe wiążące sdf-1 i ich zastosowanie
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
KR20180021234A (ko) 2013-08-12 2018-02-28 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
WO2015168468A1 (en) 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック, インコーポレイテッド 抗d因子抗体及びコンジュゲート

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053753A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US20030170864A1 (en) * 2000-05-30 2003-09-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000036102A2 (en) * 1998-12-16 2000-06-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
SE9604470D0 (sv) * 1996-12-04 1996-12-04 Tamas Bartfai Konsulting Ab Transmembrane component of tight junction
JP2001524814A (ja) * 1997-03-14 2001-12-04 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド 28種類のヒト分泌タンパク質
WO1998042739A2 (en) * 1997-03-21 1998-10-01 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1999006551A2 (en) 1997-08-01 1999-02-11 Genset 5' ESTs FOR SECRETED PROTEINS IDENTIFIED FROM BRAIN TISSUES
US20030092002A1 (en) * 1997-09-17 2003-05-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1002864A1 (en) * 1998-11-10 2000-05-24 Universita' degli studi di Bologna HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections
EE05497B1 (et) * 1999-03-11 2011-12-15 Rmf Dictagene S.A. Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
EP1533617A1 (en) 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
US7642341B2 (en) * 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer

Also Published As

Publication number Publication date
ES2361905T3 (es) 2011-06-24
EP2292761A1 (en) 2011-03-09
US20080274970A1 (en) 2008-11-06
IL145310A0 (en) 2003-01-12
WO2000053749A2 (en) 2000-09-14
CA2362896C (en) 2012-07-31
HUP0200606A3 (en) 2004-11-29
HU229376B1 (en) 2013-11-28
ZA200107283B (en) 2002-12-24
EP1163337B1 (en) 2011-03-02
CA2362896A1 (en) 2000-09-14
EE200100472A (et) 2002-12-16
NZ514091A (en) 2004-01-30
NO333085B1 (no) 2013-02-25
IS2819B (is) 2012-12-15
RU2244748C2 (ru) 2005-01-20
CZ20013267A3 (cs) 2002-02-13
JP2010233572A (ja) 2010-10-21
US20050266426A1 (en) 2005-12-01
IS6072A (is) 2001-09-10
HUP0200606A2 (en) 2002-06-29
PL350417A1 (en) 2002-12-16
CZ303128B6 (cs) 2012-04-18
US8143056B2 (en) 2012-03-27
US7393651B2 (en) 2008-07-01
HK1044169A1 (en) 2002-10-11
CN100469878C (zh) 2009-03-18
US20100267649A1 (en) 2010-10-21
CN1637019A (zh) 2005-07-13
AU4105100A (en) 2000-09-28
ATE500328T1 (de) 2011-03-15
EP1163337A2 (en) 2001-12-19
WO2000053749A3 (en) 2000-12-14
US7670826B2 (en) 2010-03-02
PL207994B1 (pl) 2011-02-28
MXPA01009110A (es) 2002-08-20
DE60045681D1 (de) 2011-04-14
JP2002537837A (ja) 2002-11-12
NO20014417D0 (no) 2001-09-11
JP4836329B2 (ja) 2011-12-14
AU782139B2 (en) 2005-07-07
NO20014417L (no) 2001-11-12
BR0008915A (pt) 2002-04-09
CN1355843A (zh) 2002-06-26

Similar Documents

Publication Publication Date Title
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
TR200001709T2 (tr) Yeni neisseria meningitids yüzey proteini
ATE255902T1 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv- verwandten krankheiten
TR200202253T2 (tr) IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
ATE431359T1 (de) Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie
DE68929043T2 (de) Für androgen-rezeptor-protein kodierende dna
DE59101889D1 (de) Variante cd44-oberflächenproteine, diese kodierende dna-sequenzen, antikörper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie.
ATE132197T1 (de) Monoklonale antikörper
KR980002066A (ko) 변이형 인간 성장호르몬 및 그의 용도
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
DE69529272T2 (de) MONOKLONALER ANTIKÖRPER GEGEN DAS HUMANE Mx-PROTEIN MxA
NO993653D0 (no) Fremgangsmåte for diagnose, prognose og behandling av glaukom og relaterte sykdommer
ATE301194T1 (de) Beta-defensine
ES2061566T3 (es) Anticuerpos monoclonales contra la proteina e7 del papilomavirus humano tipo 16, procedimiento para su preparacion, asi como su empleo.
TR200000416T2 (tr) Neisseria loctoferrin bağlayıcı protein.
DE69832197D1 (de) Rantes mutanten und deren therapeutische verwendungen
DK0870036T3 (da) Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor
DE69836278D1 (de) Allele formen von menschlichem stat3
BR0007816A (pt) Fator de estimulação óssea
DE3777359D1 (de) Aminosaeuresequenz des menschlichen alpha 2-plasmininhibitors und cdns sowie diese aminosaeuresequenz codierende genomische dns.
NO940797L (no) Reseptorderivater som har bindingseter for human-rhinovirus

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
HE1A Change of address
MM4A Lapsed by not paying the annual fees

Effective date: 20180313